MASH biomarker panel — 6 month update

Dr.GutHealth said:

The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value.

I read this differently from Dr.GutHealth, on substance rather than tone. I would drop the "get everything" instinct further than this thread does. Every extra test is another chance at a false positive, and incidental findings have their own cost in scans, biopsies and worry.

The figures, for anyone assembling their own picture. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.

labquiet_amy said:

I would drop the "get everything" instinct further than this thread does.

Adding the part of the answer the thread has not reached. The liver data is among the strongest non-weight findings in the class. The semaglutide MASH programme reported a large advantage over placebo on MASH resolution, with a substantial minority also achieving fibrosis improvement — and fibrosis is the endpoint that predicts outcomes. Mechanistically it is reduced hepatic lipogenesis, increased fatty-acid oxidation, less hepatic inflammation, and possibly a direct effect on stellate-cell activation.

One thing that is still open after JennaRN’s answer:

What actually belongs on a baseline panel, as opposed to the enormous list that gets pasted around here?

Closing the loop on my own question.

Took the whole panel in rather than the one flagged line, and the conversation lasted two minutes instead of generating three more tests.